Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
November 09 2023 - 8:00AM
Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the
“Company”), announces that President and co-CEO Sam Lee, PhD will
discuss progress in developing the novel, broad-spectrum PB2
inhibitor CC-42344 in an oral presentation, “Taking a new route:
Development of novel inhaled and oral influenza antiviral,
CC-42344” at the World Vaccine Congress West Coast on Tuesday,
November 28, 2023 at 3:20 p.m. Pacific Time. The conference is
being held November 27-30 at the Santa Clara Convention Center in
Santa Clara, Calif.
“It is highly gratifying to be selected for an
oral presentation at this prestigious gathering to discuss the
significant progress we’ve made in developing CC-42344 for the
treatment of pandemic and seasonal influenza A,” said Dr. Lee. “We
recently announced authorization by the United Kingdom Medicines
and Healthcare Products Regulatory Agency (MHRA) to initiate a
Phase 2a human challenge trial with orally administered CC-42344
and we expect to begin treating influenza-infected patients later
in this quarter. Additionally, preparations are underway to begin a
Phase 1 clinical trial in the first half of 2024 with an inhaled
CC-42344 formulation as a potential treatment and prophylaxis for
influenza A.”
Following the presentation, Cocrystal will issue
a press release with highlights from Dr. Lee’s discussion and the
slide presentation will be available on the Company’s website.
About CC-42344 CC-42344 is an
PB2 inhibitor that blocks an essential step of viral replication
and was discovered using Cocrystal’s proprietary structure-based
drug discovery platform technology. It is specifically designed to
be effective against all significant pandemic and seasonal
influenza A strains and to have a high barrier to resistance due to
the way the virus’ replication machinery is targeted. CC-42344
targets the influenza polymerase, an essential replication enzyme
with several highly essential regions common to multiple influenza
strains. In vitro testing showed CC-42344’s excellent antiviral
activity against influenza A strains, including pandemic and
seasonal strains, as well as against strains resistant to certain
approved influenza antivirals, while also demonstrating favorable
pharmacokinetic and safety profiles.
About Seasonal InfluenzaEach
year there are approximately 1 billion cases of seasonal influenza
worldwide, 3-5 million severe illnesses and up to 650,000 deaths,
according to the World Health Organization. On average about
8% of the U.S. population contracts influenza each season.
Influenza is responsible for approximately $10.4 billion in direct
costs for hospitalizations and outpatient visits for adults in the
U.S. annually.
About Cocrystal Pharma,
Inc.Cocrystal Pharma, Inc. is a clinical-stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of influenza
viruses, coronaviruses (including SARS-CoV-2) noroviruses and
hepatitis C viruses. Cocrystal employs unique structure-based
technologies and Nobel Prize-winning expertise to create first- and
best-in-class antiviral drugs. For further information about
Cocrystal, please visit www.cocrystalpharma.com.
Cautionary Note Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding the initiation and characteristics of a Phase 2a human
challenge trial in 2023 for CC-42344 as a product candidate for
oral treatment of influenza A, and a Phase 1 clinical trial in 2024
for CC-42344 as a product candidate for inhaled treatment of
influenza A, and the potential efficacy and clinical benefits of,
and market for, such product candidate. The words "believe," "may,"
"estimate," "continue," "anticipate," "intend," "should," "plan,"
"could," "target," "potential," "is likely," "will," "expect" and
similar expressions, as they relate to us, are intended to identify
forward-looking statements. We have based these forward-looking
statements largely on our current expectations and projections
about future events. Some or all of the events anticipated by these
forward-looking statements may not occur. Important factors that
could cause actual results to differ from those in the
forward-looking statements include, but are not limited to, risks
relating to the manufacturing and research delays arising from
labor shortages and other factors, the ability of our Clinical
Research Organization partners to recruit volunteers for, and to
proceed with, clinical trials, and general risks arising from or
involved in conducting clinical studies for CC-42344, including the
results of such studies. Further information on our risk factors is
contained in our filings with the SEC, including our Annual Report
on Form 10-K for the year ended December 31, 2022. Any
forward-looking statement made by us herein speaks only as of the
date on which it is made. Factors or events that could cause our
actual results to differ may emerge from time to time, and it is
not possible for us to predict all of them. We undertake no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future developments or
otherwise, except as may be required by law.
Investor Contact:LHA Investor
RelationsJody Cain310-691-7100jcain@lhai.com
Media Contact:JQA PartnersJules
Abraham917-885-7378Jabraham@jqapartners.com
# # #
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Aug 2023 to Aug 2024